Vericel (NasdaqGM:VCEL) FY Conference January 14, 2026 02:15 PM ET Company ParticipantsNick Colangelo - President and CEOConference Call ParticipantsNone - AnalystModeratorGood morning, everyone. I'm Disha Parekh. I'm an associate with the Healthcare Investment Banking Group at JPMorgan Chase. Thank you for joining us for the company presentation for Vericel Corp at the 44th Annual JPMorgan Healthcare Conference in San Francisco. Today, we are joined by Nick Colangelo, who is the President and CEO at Verice ...

Summary of Rocket Pharmaceuticals FY Conference Call (January 14, 2026) Company Overview - **Company**: Rocket Pharmaceuticals (NasdaqGM:RCKT) - **Industry**: Biotechnology, specifically focused on gene therapies for rare genetic diseases - **Core Focus**: Development of gene therapies targeting complex and rare genetic diseases, particularly in the cardiovascular space Key Points and Arguments Financial Position - As of September 30, 2025, Rocket reported **$222.8 million** in cash, cash equivalents, and restricted cash, expected to fund operations into the second quarter of **2027** [2] - Anticipated approval of **Kresladi** on March 28, 2026, could yield a **PRV** (Priority Review Voucher), providing strategic non-dilutive capital to extend the cash runway [2] Strategic Focus - 2026 is designated as a year of execution, with a concentrated effort on advancing three cardiovascular programs [2] - The company has deprioritized investments in **Fanconi anemia** to focus on areas with immediate impact [3] Cardiovascular Programs - **Danon Disease**: - A severe X-linked cardiomyopathy with a prevalence of **15,000 to 30,000** in the U.S. and Europe [8] - The lead program shows **100% LAMP2 expression** durability in treated patients, with a median reduction of **24%** in LV mass index over time [9][11] - The program is viewed as a significant near-to-medium-term value driver due to its clear differentiation and market potential [28] - **PKP2 Arrhythmogenic Cardiomyopathy (ACM)**: - Estimated to affect **50,000** adults and children in the U.S. and Europe [17] - The program is currently in phase one, with preliminary safety and efficacy results indicating well-tolerated gene therapy [18] - The company aims to define a registrational pathway for this program in 2026 [20] - **BAG3 Dilated Cardiomyopathy (DCM)**: - Considered a potential largest market opportunity with around **30,000** individuals affected in the U.S. [24] - The program is in the process of initiating a phase one trial, focusing on safety and preliminary efficacy [25] Regulatory and Clinical Development - The company is working towards resuming patient dosing for Danon disease, with logistics being the primary gating factor [29] - A concurrent natural history study for Danon is ongoing, validating the rapid decline of untreated patients [35] - The regulatory review for Kresladi is mid-cycle, with no current showstoppers noted [37] Manufacturing Capabilities - Rocket has in-house manufacturing capabilities for AAV, which helps control costs and timelines [38] - The facility is designed to support current and future programs, ensuring high margins and process improvements over time [38] Future Outlook - The anticipated approval of Kresladi is seen as a pivotal moment for transitioning to a commercial-stage gene therapy company [26] - The company plans to maintain a steady pipeline with additional programs ready to advance in the future [40] Additional Important Insights - The company emphasizes the importance of achieving meaningful myocardial transduction and protein localization for clinical benefit [21] - There is a strong community interest in the Danon program, despite past challenges, indicating a significant unmet medical need [32] - The company is cautious but optimistic about the regulatory landscape and the potential for future growth [37] This summary encapsulates the key points discussed during the conference call, highlighting Rocket Pharmaceuticals' strategic focus, financial position, and advancements in their gene therapy programs.

Silvaco Group (NasdaqGS:SVCO) FY Conference Summary Company Overview - **Company**: Silvaco Group - **Founded**: 1984 - **Industry**: Electronic Design Automation (EDA) - **Core Product Lines**: - TCAD (Technology Computer-Aided Design): Approximately 50% of revenue, a core business with a strong customer retention rate - IP (Intellectual Property): About 10% of revenue, identified as a significant growth area - Traditional EDA: Comprises the remaining revenue, focusing on niche markets to compete against larger companies like Synopsys and Cadence [3][4] Key Insights - **AI Integration**: Silvaco sees AI as a major long-term growth driver, particularly in manufacturing processes. The company aims to leverage AI to create new markets rather than just improve existing processes [5][6][7] - **Digital Twins**: The transition to virtual prototyping using AI and digital twins is essential for the semiconductor industry, allowing for more efficient process development [7][8] - **Customer Engagement**: The process of acquiring new customers for AI-driven solutions is described as a gradual engagement rather than a traditional sales approach, requiring significant collaboration and commitment from both parties [10][11] Financial Performance and Strategy - **Current Financial Status**: The company is focused on achieving profitability after experiencing losses. Plans include reducing expenses by at least $15 million annually and modest revenue growth in 2026 [19][20] - **Growth Projections**: Modest growth is anticipated due to a significant revenue spike from a major renewal in 2025 that will not recur. The company aims to overcome this loss and achieve growth [23] - **Long-term Goals**: The strategy includes building a strong AI franchise while focusing on short-term revenue growth primarily from the IP business [21][22] Market Position and Competitive Landscape - **Market Dynamics**: Silvaco operates in a highly consolidated EDA market dominated by a few large players. The company focuses on niche markets where it can maintain a competitive edge [12][16] - **Niche Specialization**: Silvaco has established itself as a leader in specific areas, such as TCAD for display manufacturing, holding over 80% market share in that segment [16][17] M&A Strategy - **Acquisition Focus**: The company has successfully acquired several firms, including Mixel, which is expected to significantly enhance Silvaco's product offerings and market position. Future acquisitions will target smaller companies with strong technology that can be integrated into Silvaco's existing framework [36][37][38] - **Cash Management**: Currently, Silvaco is focused on replenishing its cash reserves before pursuing further acquisitions [42] Challenges and Considerations - **Revenue Recognition Issues**: Silvaco faces challenges with revenue recognition due to its accounting practices, which can lead to volatility in reported earnings [45][46] - **Competitive Pricing Dynamics**: The EDA market is characterized by complex pricing strategies, where larger companies often offer discounts or free licenses to retain customers, complicating Silvaco's competitive positioning [49][50] Conclusion Silvaco Group is navigating a challenging EDA landscape with a focus on AI integration, niche market specialization, and strategic acquisitions. The company aims to achieve profitability while laying the groundwork for long-term growth through innovative technologies and customer engagement strategies.

Integra LifeSciences (NasdaqGS:IART) FY Conference January 14, 2026 02:15 PM ET Company ParticipantsLea Knight - EVP and CFOMojdeh Poul - President and CEOConference Call ParticipantsRobbie Marcus - Medtech Senior AnalystRobbie MarcusEveryone, I'm Robbie Marcus, the MedTech Analyst at JPMorgan. Very happy to introduce Integra LifeSciences CEO Mojdeh Poul. We'll give a presentation followed by some Q&A.Mojdeh PoulAll right. Thank you, Robbie. I appreciate it. Good morning, everyone, and thank you for being h ...

Annexon (NasdaqGS:ANNX) FY Conference January 14, 2026 02:15 PM ET Company ParticipantsPriyanka Grover - Political Affairs and Public Diplomacy OfficerDouglas Love - CEOJoyce Zhou - Private Equity AssociateConference Call ParticipantsAnupam Rama - Senior Biotech AnalystAnupam RamaAll right, welcome everyone to the 44th Annual J.P.Morgan Healthcare Conference. My name is Anupam Rama. I am one of the Senior Biotech Analysts here at J.P.Morgan. I'm joined by my squad: Joyce Zhou, Priyanka Grover, and Ratih Pin ...

Rapport Therapeutics (NasdaqGM:RAPP) FY Conference January 14, 2026 02:15 PM ET Company ParticipantsJeffrey Sevigny - CMOAbraham Ceesay - CEOConference Call ParticipantsNone - AnalystTyler Van Buren - AnalystAbraham CeesayOkay.OperatorYes.Abraham CeesayThank you.OperatorYou're all set. Forward that, please.Abraham CeesayGreat. Thank you.OperatorYep.Tyler Van BurenWelcome, everybody. My name is Tyler Van Buren, and I'm welcoming you to the 44th JP Morgan Healthcare Conference. Our next presentation is Rappor ...

Navitas Semiconductor (NasdaqGM:NVTS) FY Conference January 14, 2026 02:15 PM ET Company ParticipantsChris Alexander - CEOConference Call ParticipantsQuinn Bolton - AnalystQuinn BoltonOkay.Okay. We'll go ahead and get started. Good afternoon and welcome, everybody, to the second day of Needham's 28th Annual Growth Conference. My name is Quinn Bolton. I'm the semiconductor analyst for Needham & Company. It's my pleasure to host this fireside chat with Navitas Semiconductor, founded in 2014 and headquartered ...

Mirum Pharmaceuticals (NasdaqGM:MIRM) FY Conference January 14, 2026 02:15 PM ET Company ParticipantsChris Peetz - CEOConference Call ParticipantsJess Fye - Managing Director and Equity Research AnalystNone - AnalystJess FyeGreat. Good morning, everyone. My name's Jess Fye. I'm a biotech analyst at J.P. Morgan, and we're continuing our 44th annual healthcare conference this morning with Mirum. First, you're going to hear a presentation from the company, and then we're going to go into a Q&A session. So for ...

Pacira BioSciences (NasdaqGS:PCRX) FY Conference January 14, 2026 02:15 PM ET Company ParticipantsFrank Lee - CEOHardik Parikh - Equity Research of U.S. Pharma & BiotechConference Call ParticipantsNone - AnalystHardik ParikhHey, everybody. I'm Hardik Parikh at JPMorgan, covering large-cap pharmaceuticals. I am pleased to have Frank Lee here, CEO of Pacira. He's going to start off with a presentation, and then we'll end up doing a little Q&A afterwards. Thank you.Frank LeeAll right. Thank you, Hardik, for th ...

SkyWater (NasdaqCM:SKYT) FY Conference January 14, 2026 01:30 PM ET Company ParticipantsSteve Manko - CFOThomas Sonderman - CEOConference Call ParticipantsQuinn Bolton - Semiconductor AnalystQuinn BoltonWe'll go ahead and get started. Good afternoon, everybody. Welcome to the second day of Needham's 20th Annual Growth Conference. My name is Quinn Bolton. I'm the Semiconductor Analyst for Needham & Company. It's my pleasure to host this fireside chat with SkyWater Technology. The company is the largest exclu ...